Title: 213-Bismuth-labeled antibody to gp41 glycoprotein kills ART-treated lymphocytes from HIV patients and HIV-infected monocytes in human blood brain barrier model
Authors: MCFARREN ATSUKROV DEUGENIN ELOPEZ LWILLIAMS DMORGENSTERN AlfredBRUCHERTSEIFER FrankZOLLA-PAZNER S.GORNY M.k.Casadevall ArturoBERMAN JDADACHOVA E.
Citation: Proceedings of the 8th Symposium on Targeted Alpha Therapy p. 29
Publisher: Oak Ridge National Laboratory
Publication Year: 2013
JRC N°: JRC82792
URI: https://register.ornl.gov/2013/TATS/index.shtml
http://publications.jrc.ec.europa.eu/repository/handle/JRC82792
Type: Articles in periodicals and books
Abstract: Eliminating virally infected cells is an essential component of HIV eradication strategy. In addition, many patients on antiretroviral therapy (ART) suffer from HIV-associated neurocognitive disorders because the brain becomes a reservoir for infection. There is a need for drugs that can enter into the CNS and eradicate the infection. Radioimmunotherapy (RIT), a clinically established method to kill cells using radiolabeled antibodies, was recently applied to target the HIV gp41 glycoprotein expressed on the surface of infected cells.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.